Join the Psoriasis group to help and get support from people like you.
Psoriasis News (Page 4)
Related terms: Erythrodermic Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Palmo-plantar Psoriasis, Psoriasis vulgaris, Pustular Psoriasis
FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira
September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved...
FDA Approves Inflectra (infliximab-dyyb) a Biosimilar to Remicade
April 5, 2016 – The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second...
FDA Approves Taltz (ixekizumab) for Plaque Psoriasis
March 22, 2016 – The U.S. Food and Drug Administration today approved Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes patches...
Promius Pharma Receives FDA Approval for Sernivo (betamethasone dipropionate) Spray
HYDERABAD, India & PRINCETON, N.J., February 07, 2016 --(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has r...
Novartis Receives FDA Approval for Cosentyx (secukinumab) to Treat Patients with Ankylosing Spondylitis and Psoriatic Arthritis
EAST HANOVER, N.J., Jan. 15, 2016 Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for two new indications - the treatment of adult...
LEO Pharma Announces U.S. Approval of Enstilar Foam (calcipotriene/betamethasone dipropionate) for Plaque Psoriasis
Ballerup, Denmark 19 October, 2015: LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved Enstilar (calcipotriene/betamethasone dipropionate 50 micrograms/g / 0,5...
FDA Approves Cosentyx (secukinumab) for Plaque Psoriasis
January 21, 2015 – The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis. Psoriasis is a skin condition that causes...
FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of...
FDA Approves Rasuvo (methotrexate) Injection
Chicago, IL, July 14, 2014 – Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced...
Otrexup (Methotrexate) Injection Approved By FDA
EWING, N.J., October 14, 2013 — Antares Pharma, Inc. today announced the approval of Otrexup (methotrexate) injection by the U.S. Food and Drug Administration (FDA). Otrexup is the first FDA approved ...
Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%
Research Triangle Park, N.C. – October 12, 2010 – Stiefel, a GSK company, today announced that the U.S. Food and Drug Administration (FDA) has approved Sorilux (calcipotriene) Foam, 0.005%, for the to...
FDA Approves Stelara (ustekinumab) to Treat Psoriasis
September 25, 2009 - The U.S. Food and Drug Administration today approved Stelara (ustekinumab), a biologic product for adults who have a moderate to severe form of psoriasis. Plaque psoriasis is an...
Further information
Related condition support groups
Plaque Psoriasis, Dermatological Disorders
Related drug support groups
prednisone, methylprednisolone, methotrexate, Humira, triamcinolone, clobetasol, fluocinonide, Stelara, Remicade, view more... prednisolone, Cosentyx, Skyrizi, dexamethasone, adalimumab, etanercept, desonide, halobetasol, ustekinumab, Cimzia, Therapeutic, Taltz